Atherosclerosis Pipeline Analysis Report 2025

Atherosclerosis is a condition where arteries narrow due to plaque buildup, restricting blood flow and increasing the risk of cardiovascular events. It accounts for a significant portion of global cardiovascular disease (CVD) cases, which caused 20.5 million deaths in 2021, according to the World Heart Federation. With limited treatment options, there is a growing focus on better therapies, including targeted biologics and anti-inflammatory drugs. The atherosclerosis pipeline analysis by the publisher highlights several promising atherosclerosis therapeutics in development. Advancements in drug delivery, genetic research, and increased R&D investment are expected to drive substantial pipeline growth in the coming years.

Report Coverage

The Atherosclerosis Pipeline Analysis Report by the publisher gives comprehensive insights into atherosclerosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for atherosclerosis. The atherosclerosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The atherosclerosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with atherosclerosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to atherosclerosis.

Atherosclerosis Pipeline Outlook

Atherosclerosis is a condition where arteries become narrowed and hardened due to plaque buildup, primarily composed of fats, cholesterol, and inflammatory cells. This process begins when damage occurs to the arterial walls, triggering an immune response. Over time, the accumulation of fatty deposits and chronic inflammation restricts blood flow, increasing the risk of heart attacks and strokes.

Atherosclerosis treatment includes lifestyle changes, cholesterol-lowering drugs, antiplatelet agents, and anti-inflammatory therapies to reduce plaque buildup and prevent cardiovascular events. In June 2023, the U.S. Food and Drug Administration approved LODOCO (colchicine, 0.5 mg tablet) as the first anti-inflammatory drug to lower cardiac event risks in atherosclerotic cardiovascular disease by 31% on top of standard therapies.

Atherosclerosis Epidemiology

According to the World Heart Federation, cardiovascular diseases remain a global health challenge, with 20.5 million deaths reported in 2021. Ischaemic heart disease is the leading cause of premature death in 146 countries for men and 98 for women. The United States, EU-4, the United Kingdom, Japan, and India report varied incidence rates. High-income regions show lower death rates, while Central Europe, Eastern Europe, and Central Asia continue to exhibit the highest age-standardized cardiovascular mortality.

Atherosclerosis - Pipeline Therapeutic Assessment

This section of the report covers the analysis of atherosclerosis drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Peptides
• Nucleic Acid-Based Therapies
• Gene Therapy
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Atherosclerosis Pipeline Assessment Segmentation by Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase IV covers a major share at 28.29% of the total atherosclerosis clinical trials. Followed by Phase III at 26.32%, Phase II at 23.68%, Phase I at 14.47%, and Early Phase I at 7.24%. This strong late-stage pipeline highlights significant progress in clinical development, offering promising therapeutic advancements and positively influencing growth and innovation in the atherosclerosis market.

Atherosclerosis Pipeline Assessment Segmentation by Drug Classes

The drug molecule categories covered under the atherosclerosis pipeline analysis include small molecules, monoclonal antibodies, peptides, nucleic acid-based therapies, gene therapy, and others. The atherosclerosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for atherosclerosis.

Lipid-lowering therapies continue to play a pivotal role in the treatment of atherosclerosis. For example, YN001, a liposome-encapsulated formulation of Rosuvastatin calcium, is under development to enhance targeted delivery. It utilizes the CD44-active targeting ability of HPD, a liposomal component, to enrich Rosuvastatin in atherosclerotic plaques, potentially improving therapeutic outcomes and plaque stability.

Atherosclerosis Clinical Trials - Key Players

The report for the atherosclerosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed atherosclerosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in atherosclerosis clinical trials:

• AstraZeneca
• Novartis Pharmaceuticals
• Beijing Inno Medicine Co., Ltd.
• Amgen
• NewAmsterdam Pharma
• CSL Behring
• Eli Lilly and Company
• Cyclarity Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• Fortrea Holdings Inc.
• Samjin Pharmaceutical Co., Ltd.

Atherosclerosis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for atherosclerosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of atherosclerosis drug candidates.

Drug: Pelacarsen (TQJ230

)
Pelacarsen is being sponsored by Novartis Pharmaceuticals in a Phase III rollover extension study. Pelacarsen is a liver-targeted antisense oligonucleotide designed to inhibit apolipoprotein(a) production, thereby significantly lowering Lp(a) levels. This trial is evaluating the long-term safety and tolerability of Pelacarsen in patients with elevated Lp(a) and established atherosclerotic cardiovascular disease (ASCVD).

Drug: AZD0780

AZD0780 is being developed by AstraZeneca and is part of a Phase II clinical trial, where it is evaluated for its effect on systolic blood pressure in patients with ASCVD or risk equivalents. AZD0780 is a PCSK9 inhibitor, working to reduce LDL cholesterol levels, thereby aiming to lower the risk of cardiovascular events like heart attacks and strokes. The study uses 24-hour ambulatory monitoring.

Drug: UDP-003

UDP-003, sponsored by Cyclarity Therapeutics, is currently undergoing an early-phase, placebo-controlled clinical trial to evaluate its safety, pharmacokinetics, and pharmacodynamics in healthy individuals and patients with atherosclerotic cardiovascular disease. The study aims to determine UDP-003’s potential efficacy in reducing arterial plaque burden. This investigational drug targets 7-ketocholesterol, an oxidized form of cholesterol that accumulates with age and contributes to plaque formation. Administered as an intravenous injection, UDP-003 is designed to stimulate macrophages to clear plaque by transforming foam cells back into functional immune cells, thereby promoting arterial repair and improving cardiovascular health.

Reasons To Buy This Report

The Atherosclerosis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for atherosclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the atherosclerosis pipeline insights.

Key Questions Answered in the Atherosclerosis Pipeline Insight Report

• Which companies/institutions are leading the atherosclerosis drug development?
• What is the efficacy and safety profile of atherosclerosis pipeline drugs?
• Which company is leading the atherosclerosis pipeline development activities?
• What is the current atherosclerosis commercial assessment?
• What are the opportunities and challenges present in the atherosclerosis pipeline landscape?
• What is the efficacy and safety profile of atherosclerosis pipeline drugs?
• Which company is conducting major trials for atherosclerosis drugs?
• Which companies/institutions are involved in atherosclerosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in atherosclerosis?

This product will be delivered within 3-5 business days.